STOCK TITAN

PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

PDL BioPharma (Nasdaq: PDLI) will release its third quarter 2020 financial results on November 9, 2020, after market close. The management will conduct a conference call at 4:30 p.m. ET to discuss the results and update on asset monetization efforts. A slide presentation will be available via the webcast on PDL's website. PDL is focused on unlocking value through asset monetization as it pursues a formal liquidation process following stockholder approval for a Plan of Dissolution.

Positive
  • None.
Negative
  • Pursuing a formal process to liquidate and dissolve the Company.
  • Set to navigate financial results amid a challenging operational environment.

INCLINE VILLAGE, Nev., Oct. 29, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020, on Monday, November 9, 2020 after market close.  PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss financial results and provide an update on its progress in monetizing the Company's assets.  A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.

Conference Call Details
We encourage participants to pre-register for the conference call using the following link: https://dpregister.com/sreg/10149211/db6bb6ea0d.  Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.  Participants may pre-register at any time, including up to and after the call start time.

Those who choose not to pre-register can access the live conference by dialing (833) 685-0901 from the United States or (412) 317-5734 internationally.  The conference ID is 10149211.  Please dial in approximately 10 minutes prior to the start of the call.  A telephone replay will be available for one week following the call and may be accessed by dialing (877) 344-7529 from the United States, (855) 669-9658 from Canada or (412) 317-0088 internationally. The replay passcode is 10149211.

To access the live and subsequently archived webcast of the conference call, go to "Events & Presentations" on the Company's website.  Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies.  PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases.  In 2006, the Company changed its name to PDL BioPharma, Inc.

As of December 2019, PDL ceased making additional strategic transactions and investments and is pursuing a formal process to unlock the value of its portfolio by monetizing its assets and ultimately distributing net proceeds to stockholders in the form of cash or equity.  On August 19, 2020, PDL announced at the Company's 2020 Annual Meeting of Stockholders approval by stockholders for a Plan of Dissolution authorizing the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution.

For more information please visit https://www.pdl.com/

NOTE:  PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein.

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-third-quarter-2020-financial-results-and-provide-a-business-update-on-november-9-2020-301162662.html

SOURCE PDL BioPharma, Inc.

FAQ

When will PDL BioPharma announce its third quarter 2020 financial results?

PDL BioPharma will announce its third quarter 2020 financial results on November 9, 2020.

What time is the PDL BioPharma conference call?

The conference call will be held at 4:30 p.m. Eastern time on November 9, 2020.

What is the focus of PDL BioPharma's business update?

The business update will focus on financial results and the progress in monetizing the Company's assets.

What is the Plan of Dissolution approved by PDL stockholders?

The Plan of Dissolution authorizes the Company to liquidate and dissolve its operations.

Where can I find the webcast for the PDL BioPharma conference call?

The webcast will be available on the PDL BioPharma website under the Events & Presentations section.

PDLI

NASDAQ:PDLI

PDLI Rankings

PDLI Latest News

PDLI Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Incline village